why choose us

First received: March 03, 2023

Clinical Trial: Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

Study Status: Completed

Recruit Status: RECRUITING

Condition: Hepatocellular Carcinoma

Study Type: INTERVENTIONAL


Official Title: Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

Brief Summary: There is an unmet need for patients with intermediate stage hepatocellular carcinoma (HCC).It is known that local tumor ablation can increase tumor immunogenicity by releasing tumor associated antigens, potentially increasing the response to immune therapy not just locally, but systemically.In addition, there is now positive data with immune therapy in advanced HCC, there is renewed interest in the combination of local therapy and systemic therapy in Barcelona Clinic Liver Clinic B (BCLC B) patients with systemic…

Read more